Dr. Spyros Artavanis-Tsakonas
Next up is Biogen Idec who has appointed Dr. Spyros Artavanis-Tsakonas as Chief Scientific Officer.
Dr. Artavanis-Tsakonas served as interim CSO while on sabbatical from Harvard Medical School and will continue in this role in a permanent capacity.
Doug Williams, Executive Vice President of Research and Development, said: “He will continue what he has successfully started at Biogen Idec—attracting and encouraging exceptional scientific talent, enhancing our existing early discovery programs, establishing extensive academic collaborations and leading our drug discovery strategy.”